CL2015002535A1 - Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis - Google Patents

Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis

Info

Publication number
CL2015002535A1
CL2015002535A1 CL2015002535A CL2015002535A CL2015002535A1 CL 2015002535 A1 CL2015002535 A1 CL 2015002535A1 CL 2015002535 A CL2015002535 A CL 2015002535A CL 2015002535 A CL2015002535 A CL 2015002535A CL 2015002535 A1 CL2015002535 A1 CL 2015002535A1
Authority
CL
Chile
Prior art keywords
aromatic compounds
fibrosis
treatment
compounds substituted
related method
Prior art date
Application number
CL2015002535A
Other languages
English (en)
Spanish (es)
Inventor
Boulos Zacharie
Shaun Abbott
Lyne Gagnon
Pierre Laurin
Brigitte Grouix
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of CL2015002535A1 publication Critical patent/CL2015002535A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
CL2015002535A 2013-03-15 2015-09-09 Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis CL2015002535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361798269P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
CL2015002535A1 true CL2015002535A1 (es) 2016-03-28

Family

ID=51535669

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002535A CL2015002535A1 (es) 2013-03-15 2015-09-09 Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis

Country Status (25)

Country Link
US (3) US10023518B2 (enExample)
EP (1) EP2970089B1 (enExample)
JP (1) JP6448562B2 (enExample)
KR (1) KR102196721B1 (enExample)
CN (2) CN110105200B (enExample)
AR (1) AR095429A1 (enExample)
AU (1) AU2014231648B2 (enExample)
BR (1) BR112015022008A2 (enExample)
CA (1) CA2905621C (enExample)
CL (1) CL2015002535A1 (enExample)
DK (1) DK2970089T3 (enExample)
EA (1) EA030651B1 (enExample)
ES (1) ES2741439T3 (enExample)
IL (1) IL241178B (enExample)
MX (1) MX379424B (enExample)
MY (1) MY180305A (enExample)
NZ (1) NZ712797A (enExample)
PH (1) PH12015502011B1 (enExample)
PL (1) PL2970089T3 (enExample)
PT (1) PT2970089T (enExample)
SG (1) SG11201507408XA (enExample)
TW (1) TWI689490B (enExample)
UY (1) UY35402A (enExample)
WO (1) WO2014138906A1 (enExample)
ZA (1) ZA201507061B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
KR20170066614A (ko) * 2014-10-10 2017-06-14 프로메틱 파마 에스엠티 리미티드 당뇨병의 예방 및 치료를 위한 치환된 방향족 화합물 및 약제학적 조성물
BR112017007426A2 (pt) * 2014-10-10 2018-01-16 Prometic Pharma Smt Limited compostos aromáticos substituídos e composições farmacêuticas para prevenir e tratar osteoporose
KR20170072352A (ko) 2014-11-12 2017-06-26 프로메틱 파마 에스엠티 리미티드 조직 자가-회복 및 재생을 위한 치환된 방향족 화합물 및 약제학적 조성물
MX376504B (es) * 2015-03-18 2025-03-07 Vectus Biosystems Ltd Composiciones para el tratamiento de enfermedades renales y/o hepaticas.
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
HK1254295A1 (zh) 2015-11-23 2019-07-19 默克专利股份有限公司 用於治疗纤维化和/或纤维化病症的抗-αV整合素抗体
US10463645B2 (en) * 2016-05-19 2019-11-05 Everfront Biotech Inc. Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102126389B1 (ko) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
SG11202103011YA (en) 2018-10-11 2021-04-29 Basf As Aromatic compounds and pharmaceutical uses thereof
US20240043372A1 (en) * 2020-10-06 2024-02-08 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
US20070276042A1 (en) * 2006-05-26 2007-11-29 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
JP5544169B2 (ja) * 2007-02-08 2014-07-09 エミスフェアー・テクノロジーズ・インク フェニルアルキルカルボン酸誘導体送達剤
CA2761061A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof
EA022445B1 (ru) * 2009-05-04 2016-01-29 Прометик Байосайенсиз Инк. Замещенные ароматические соединения, композиции на их основе и их фармацевтические применения
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale

Also Published As

Publication number Publication date
US11524930B2 (en) 2022-12-13
NZ712797A (en) 2020-08-28
HK1220440A1 (en) 2017-05-05
PH12015502011A1 (en) 2016-01-11
US10550066B2 (en) 2020-02-04
US20200172462A1 (en) 2020-06-04
TW201441186A (zh) 2014-11-01
TWI689490B (zh) 2020-04-01
MX2015011878A (es) 2016-06-07
EA030651B1 (ru) 2018-09-28
PT2970089T (pt) 2019-09-04
IL241178A0 (en) 2015-11-30
DK2970089T3 (da) 2019-08-05
JP2016512202A (ja) 2016-04-25
WO2014138906A1 (en) 2014-09-18
IL241178B (en) 2020-09-30
EA201591775A1 (ru) 2016-05-31
CN110105200A (zh) 2019-08-09
EP2970089A4 (en) 2016-10-12
KR20160051676A (ko) 2016-05-11
MX379424B (es) 2025-03-11
CN110105200B (zh) 2022-04-12
PH12015502011B1 (en) 2020-12-04
UY35402A (es) 2014-10-31
JP6448562B2 (ja) 2019-01-09
SG11201507408XA (en) 2015-10-29
AU2014231648A1 (en) 2015-10-22
CA2905621A1 (en) 2014-09-18
US20160039736A1 (en) 2016-02-11
KR102196721B1 (ko) 2020-12-30
AR095429A1 (es) 2015-10-14
AU2014231648B2 (en) 2018-02-08
PL2970089T3 (pl) 2020-01-31
US20180237374A1 (en) 2018-08-23
ES2741439T3 (es) 2020-02-11
CN105189438A (zh) 2015-12-23
US10023518B2 (en) 2018-07-17
MY180305A (en) 2020-11-27
ZA201507061B (en) 2017-03-26
BR112015022008A2 (pt) 2021-05-25
EP2970089B1 (en) 2019-05-08
EP2970089A1 (en) 2016-01-20
CA2905621C (en) 2021-06-29

Similar Documents

Publication Publication Date Title
CL2015002535A1 (es) Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
CL2015003731A1 (es) Inhibidores de bromodominios
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
IL256206A (en) Mct4 inhibitors for treating disease
BR112016021034A2 (pt) Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit
CO2017003699A2 (es) Compuesto heterocíclico
BR112014013694A2 (pt) método para tratar uma doença, e, kit
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
UY36286A (es) Tratamientos médicos basados en anamorelina
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
EA201791945A1 (ru) Пирролидинкарбоксамидопроизводные и способы их получения и их применение
EP4268891A3 (en) Compound for use in methods for treatment of polycystic kidney disease
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
PL3250042T3 (pl) Kompozycja, sposób, zastosowanie i wyrób
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
WO2014140856A3 (en) Mir-142 and antagonists thereof for treating disease